<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106038</url>
  </required_header>
  <id_info>
    <org_study_id>LICOR-10417-01</org_study_id>
    <nct_id>NCT03106038</nct_id>
  </id_info>
  <brief_title>Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery</brief_title>
  <official_title>A Phase I/IIa Dose-escalation Study to Evaluate the Use of an Investigational Imaging Agent for the Detection of Urologic Anatomy Via Near Infrared Fluorescence Imaging in the Setting of Minimally Invasive Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Li-Cor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Li-Cor, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to study the safety and efficacy of an investigational
      imaging agent for delineation/visualization of urologic anatomy in the setting of minimally
      invasive surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2017</start_date>
  <completion_date type="Actual">November 19, 2018</completion_date>
  <primary_completion_date type="Actual">November 19, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>beginning at the estimated target dose, the dosage was increased and decreased to confirm the near-optimal dose.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of Treatment-Emergent Serious Adverse Events and/or Treatment-Emergent Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose response</measure>
    <time_frame>10 minutes through 90 minutes post administration</time_frame>
    <description>Dose response based on the composite assessment of the anatomy and laterality for detection of pelvic ureter in women undergoing minimally invasive surgery</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Intraoperative Ureter Injury</condition>
  <arm_group>
    <arm_group_label>Nerindocianine for Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Arm: Nerindocianine for Injection (Initial dosing cohort: 0.06 mg/kg body weight); solution, intravenous, one time administration during surgery. the study has only one arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nerindocianine for Injection</intervention_name>
    <description>Procedure: routine minimally invasive pelvic surgery.</description>
    <arm_group_label>Nerindocianine for Injection</arm_group_label>
    <other_name>IRDye 800BK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent prior to the initiation of study procedures

          -  Are &gt; 18 years of age

          -  Women consented to undergo standard of care minimally invasive pelvic surgery
             (traditional laparoscopy and robotic surgery)

          -  Women who are expected to be admitted to the hospital following surgery for at least
             24 hours

        Exclusion Criteria:

          -  Are unwilling or unable to provide informed consent.

          -  Are unwilling or unable to comply with the requirements of the protocol.

          -  History of prior urologic surgery.

          -  History of prior pelvic surgery.

          -  History of known retroperitoneal fibrosis.

          -  Have any of the following screening laboratory values:

               -  Hemoglobin ≤ 8.0 g/dL;

               -  Absolute neutrophil count (ANC) ≤ 1500/μL;

               -  Platelet count ≤ 100,000/μL;

               -  Serum creatinine ≥ 1.5 x the institutional upper limit of normal (IULN)
                  creatinine;

               -  Serum bilirubin ≥ 1.5 x IULN;

               -  Aspartate transaminase (AST or serum glutamic oxaloacetic transaminase, SGOT) ≥
                  2x IULN;• Alanine transaminase (ALT or serum glutamate pyruvate transaminase,
                  SGPT) ≥ 2 x IULN.

          -  Females who are pregnant, lactating, or breastfeeding;

          -  Any other condition that, in the Investigator's judgment, would potentially compromise
             the study compliance or the ability to evaluate safety or efficacy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth H. Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Women &amp; Infants Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <disposition_first_submitted>November 15, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>November 15, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 20, 2019</disposition_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contrast agent</keyword>
  <keyword>ureter imaging</keyword>
  <keyword>intraoperative monitoring</keyword>
  <keyword>intraoperative procedures</keyword>
  <keyword>near infrared fluorescence</keyword>
  <keyword>minimally invasive</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

